Current insights on the risk of thrombogenicity with off-label use of rFVIIa

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 1, 2006, Pages 34-35

  Key, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; HEART INFARCTION; HEMOPHILIA; HUMAN; OFF LABEL DRUG USE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOGENICITY;

AGED; FACTOR VII; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; RISK FACTORS; THROMBOSIS;

EID: 31744446734     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Mayer SA, Brun NC, Begtrup K, et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
2. MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion. 2005;45:1434-1442.
3. Enomoto TM, Thorborg P. Emerging off-label uses for recombinant activated factor VII: grading the evidence. Crit Care Clin. 2005;21:611-632.
4. Recombinant FVIIa in the management of intracerebral hemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med. 2005;15:145-150.